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Editorial on the Research Topic
Recent Advances in Cardiotoxicity Testing
INTRODUCTION
Drug induced cardiotoxicity is a major cause of market withdrawal (Onakpoya et al., 2016). In the
last decade of the 20th century, eight non-cardiovascular drugs were withdrawn from clinical use
because they prolonged the QT interval (Fermini and Fossa, 2003), resulting in ventricular
arrhythmias and potentially sudden death. In particular, the last decade has seen an explosion of
cancer therapies, which while effective can lead to several cardiovascular toxicities. Both traditional
(e.g., anthracyclines and radiation) and targeted (e.g., trastuzumab) therapies can result in
cardiovascular complications in a subset of patients (Groarke et al., 2013; Moslehi, 2016). A
close collaboration between cardiologists and oncologists (via the emerging field of “cardio-
oncology”) had helped make these complications manageable ensuring that patients can be
treated effectively (Campia et al., 2019). An explosion of novel therapies which include newer
kinase inhibitors, proteolysis-targeting chimera (PROTAC) and immune-based therapies expand the
oncology armamentarium, each drug with its own potential cardiovascular toxicity (Sheng et al.,
2016; Fleming et al., 2021). Therefore, there is a growing need for reliable preclinical screening
strategies for CV toxicities associated with emerging breast cancer therapies prior to human clinical
trials. The most prevalently used cardiac physiology screening platform are animal models that have
limited reliability in mirroring the effects of drugs in human hearts (Liu et al., 2006; Salama and Bett,
2014; Asnani et al., 2021). Additionally, the use of animal models to create a pharmacokinetic profile
of drugs is relatively expensive at the early development stage since large amounts of the drugs are
used (Guth et al., 2019). Ultimately, the ideal experimental cardiac tissue culture model is the one that
demonstrates high sensitivity and specificity towards various therapeutic and pharmacological
interventions while accurately replicating the physiology and pathophysiology of the human heart
(Wang et al., 2008). The recent move towards the use of human induced pluripotent stem cell-
derived cardiomyocytes (hiPS-CMs) (Burridge et al., 2016) and human heart slices (Ou et al., 2019;
Miller et al., 2020; Ou et al., 2020) in cardiotoxicity testing provided a potential solution to address
this issue. In this special issue we have 12manuscripts, seven review articles and five original research
articles summarizing the recent advances in cardiotoxicity testing.
Jaeger et al. used a novel computer simulation to identifying drug response through combining
several assessments of the membrane potential, the cytosolic calcium concentration, and the
extracellular potential in microphysiological systems. In another effort for in silico modeling of
cardiotoxicity, Paci et al., assessed the response of three human stem cell derived cardiomyocytes
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(hSC-CMs) in silico models to simulate drug action, and compare
simulation results against in vitro data for 15 drugs. Furthermore,
in an effort to create a novel high-throughput platform to detect
cardiotoxicity for atrial arrhythmias, Honda et al. (2021) created
and validated a high-throughput drug screening system based on
hiPS-derived-atrial myocytes. In the same vein, Verkerk et al.
optimized a dynamic clamp system to obtain patch-clamp
recordings of action potentials from adult primary human
atrial myocytes. This technology will be useful in detecting
arrhythmogenic cardiotoxins on adult human hearts. The
same first author, Dr. Verkerk with other team of
collaborators have modeled a prominent cause of arrhythmia
in patients with a deficiency in very long-chain acyl-CoA
dehydrogenase (VLCAD), an enzyme that is involved in the
mitochondrial beta-oxidation of long-chain fatty acids. They
generated hiPSC-CMs from VLCAD deficiency patients and
they tested the effect of carnitine supplement on attenuating
the arrhythmic potential; however, it was not effective.
This special issue includes seven great reviews and
perspectives of different topics related to cardiotoxicity
testing. Szabo et al. provided a perspective regarding novel
anticancer therapeutics to prevent tumorigenesis without
cardiotoxic effects highlighting a new family of therapeutics
including ERK dimerization inhibitors and BAX allosteric
inhibitors. Campana et al. provided a perspective regarding
the role of inflammation in cardiotoxicity and how
inflammation should be accounted for during drug screening
in early stages of drug development. Thomas et al., Keung et al.,
and Orsolits et al. have provided three comprehensive reviews
for the cellular and tissue models derived from hiPS cells and
their recent uses to assess cardiotoxicity of cancer therapies.
Furthermore, Tu et al. wrote a mini review regarding the use of
hiPS-derived cells as a screening platform for drug-induced
vascular toxicity. hiPSC-CM systems are ideal for high-
throughput testing and for proof-of-principle evaluations of
patient-specific genetic backgrounds or disease mutations;
however, the incomplete maturation and lack of
multicellularity creates caveats. The use of slice preparations
is an exciting advance in test platforms because this native
tissue preparation retains phenotypic properties in vitro (Ou
et al., 2019; Miller et al., 2020; Ou et al., 2020). Finally, Meki
et al. reviewed the use of adult human and pig heart slices in
cardiotoxicity testing.
Overall, this special issue provides an overview of the novel
platforms used for cardiotoxicity testing. This field of research is
evolving rapidly, and it ultimately holds promise for more reliable
and sensitive drug and chemical screening.
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